TITLE

Antiviral Activity of Single-Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV-Infected Adults

AUTHOR(S)
Jacobson, Jeffrey M.; Saag, Michael S.; Thompson, Melanie A.; Fischl, Margaret A.; Liporace, Ralph; Reichman, Richard C.; Redfield, Robert R.; Fichtenbaum, Carl J.; Zingman, Barry S.; Patel, Mahesh C.; Murga, Jose D.; Pemrick, Suzanne M.; d'Ambrosio, Paul; Michael, Marti; Kroger, Hans; Hieu Ly; Rotshteyn, Yakov; Buice, Robert; Morris, Stephen A.; Stavola, Joseph J.
PUB. DATE
November 2008
SOURCE
Journal of Infectious Diseases;11/1/2008, Vol. 198 Issue 9, p1345
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. The current goal of human immunodeficiency virus type 1 (HIV-1) therapy is to maximally suppress viral replication. Securing this goal requires new drugs and treatment classes. The chemokine receptor CCR5 provides an entry portal for HIV-1, and PRO 140 is a humanized monoclonal antibody that binds to CCR5 and potently inhibits CCR5-tropic (R5) HIV-1 in vitro. Methods. A randomized, double-blind, placebo-controlled, dose-escalating study was conducted in 39 individuals with HIV-1 RNA levels ⩾5000 copies/mL, CD4+ cell counts ⩾250 cells/μL, no antiretroviral therapy for 3 months, and only R5 HIV-1 detectable. Cohorts were randomized 3:10 to receive placebo or doses of PRO 140 of 0.5, 2, or 5 mg/kg. Subjects were monitored for 58 days for safety, antiviral effects, and serum concentrations of PRO 140. Results. PRO 140 was generally well tolerated and demonstrated potent, rapid, prolonged, and dose-dependent antiviral activity. Mean reductions in HIV-1RNAlevel of 0.58 log10, 1.20 log10 (P = .0002) and 1.83 log10 (P < .0001) were observed for the 0.5-, 2-, and 5-mg/kg dose groups, respectively. Reductions in mean viral load of ⩾10-fold were observed within 4 days and persisted for 2-3 weeks after treatment. Conclusions. This trial established clear proof of concept for PRO 140 as a potent antiretroviral agent with extended activity after a single dose. Trial registration. ISRCTN Register: ISRCTN45537485.
ACCESSION #
35134353

 

Related Articles

  • Caught in translation: innate restriction of HIV mRNA translation by a schlafen family protein. Jakobsen, Martin R; Mogensen, Trine H; Paludan, Søren R // Cell Research;Mar2013, Vol. 23 Issue 3, p320 

    Human immunodeficiency virus type 1 (HIV-1) is the cause of AIDS. In recent years it has emerged that cellular interferon-stimulated genes (ISG), play important roles in cell-intrinsic restriction of HIV replication. A publication now describes a novel strategy employed by HIV-infected cells to...

  • The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Ramratnam, Bharat; Mittler, John E.; Zhang, Linqi; Boden, Daniel; Hurley, Arlene; Fang, Fang; Macken, Catherine A.; Perelson, Alan S.; Markowitz, Martin; Ho, David D. // Nature Medicine;Jan2000, Vol. 6 Issue 1, p82 

    Replication-competent HIV-1 can be isolated from infected patients despite prolonged plasma virus suppression by anti-retroviral treatment. Recent studies have identified resting, memory CD4[sup +] T lymphocytes as a long-lived latent reservoir of HIV-1 (refs. 4,5). Cross-sectional analyses...

  • Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection. Squires, Kathleen; Pozniak, Anton L.; Pierone, Gerald; Steinhart, Corkiin R.; Berger, Daniel; Belios, Nicholaos C.; Becker, Stephen L.; Wulfsohn, Michael; Miller, Michael D.; Toole, John J.; Coakiey, Dion F.; Andrew Cheng // Annals of Internal Medicine;9/1/2003 Part 1, Vol. 139 Issue 5, p313 

    Background: Resistance to antiretroviral agents remains a leading cause of treatment failure for patients infected with HIV-1. Objective: To describe the efficacy and safety of tenofovir disoproxil fumarate (tenofovir DF) compared with placebo in patients with detectable viral replication...

  • A role for CD81 on the late steps of HIV-1 replication in a chronically infected T cell line. Grigorov, Boyan; Attuil-Audenis, Valérie; Perugi, Fabien; Nedelec, Martine; Watson, Sarah; Pique, Claudine; Darlix, Jean-Luc; Conjeaud, Hélène; Muriaux, Delphine // Retrovirology;2009, Vol. 6, p1 

    Background: HIV-1 uses cellular co-factors for virion formation and release. The virus is able to incorporate into the viral particles host cellular proteins, such as tetraspanins which could serve to facilitate HIV-1 egress. Here, we investigated the implication of several tetraspanins on HIV-1...

  • In Vivo Emergence of HIV-1 Highly Sensitive to Neutralizing Antibodies. Aasa-Chapman, Marlén M. I.; Cheney, Kelly M.; Hué, Stéphane; Forsman, Anna; O'Farrell, Stephen; Pellegrino, Pierre; Williams, Ian; McKnight, Áine // PLoS ONE;2011, Vol. 6 Issue 8, p1 

    Background: The rapid and continual viral escape from neutralizing antibodies is well documented in HIV-1 infection. Here we report in vivo emergence of viruses with heightened sensitivity to neutralizing antibodies, sometimes paralleling the development of neutralization escape....

  • Cross-Neutralizing Human Monoclonal Anti-HIV-1 Antibody 2F5: Preparation and Crystallographic Analysis of the Free and Epitope-Complexed Forms of its F ab Fragment. Bryson, Steve; Cunningham, Annie; Ho, Jason; Hynes, Rosemary C.; Isenman, David E.; Barber, Brian H.; Kunert, Renate; Katinger, Hermann; Klein, Michel; Pai, Emil F. // Protein & Peptide Letters;Aug2001, Vol. 8 Issue 5, p413 

    The human monoclonal antibody 2F5 is a potent neutralizer of most clades of HIV-1 and possesses protective effects against viral transmission. It recognizes the linear epitope ELDKWAS of the viral envelope protein gp41. As structural information about epitope recognition may help to develop an...

  • Identification of Authentic Inhibitors of HIV-1 Integration. Witvrouw, M.; Fikkert, V.; Vercammen, J.; Van Maele, B.; Engelborghs, Y.; Debyser, Z. // Current Medicinal Chemistry - Anti-Infective Agents;Apr2005, Vol. 4 Issue 2, p153 

    Current strategies for the treatment of human immunodeficiency virus (HIV) infection are based on cocktails of drugs that target the viral entry step and the enzymes reverse transcriptase or protease. At present, the clinical benefit of this combination therapy for HIV-infected patients is...

  • Evolution of HIV-1 in an HLA-B*57—Positive Patient during Virologic Escape. Bailey, Justin R.; Zhang, Haili; Wegweiser, Barbara W.; Hung-Chih Yang; Herrera, Laura; Ahonkhai, Aima; Williams, Thomas M.; Siliciano, Robert F.; Blankson, Joel N. // Journal of Infectious Diseases;7/1/2007, Vol. 196 Issue 1, p50 

    Elite suppressors maintain normal CD4+ T cell counts and viral loads of <50 copies of human immunodeficiency virus type 1 (HIV-1) RNA per milliliter of plasma without antiviral therapy.We report here a case of virologic escape in a human leukocyte antigen (HLA)—B*57-positive patient...

  • Safety, Pharmacokinetics, and Antiviral Activity of HGSOO4, a Novel Fully Human IgG4 Monoclonal Antibody against CCR5, in H1V-1—Infected Patients. Lalezari, Jacob; Yadavalli, Gopal K.; Para, Michael; Richmond, Gary; DeJesus, Edwin; Brown, Stephen J.; Cai, Wendy; Chen, Cecil; Zhong, John; Novello, Lu Anne; Lederman, Michael M.; Subramanian, G. Mani // Journal of Infectious Diseases;3/1/2008, Vol. 197 Issue 5, p721 

    Background. HGS004 is a fully human immunoglobulin (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5) with robust in vitro activity against a diverse panel of CCR5-tropic human immunodeficiency virus type 1 (HIV-1) isolates. Methods. A single-blind, randomized, placebo-controlled...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics